

REMARKS

Claims 34, 35, and 37-56 are now in the application. No claims have been amended by this Response. No new matter has been added.

Applicants appreciate the courtesies extended to Applicants' representative by Examiner Gillespie during the July 7, 2009 telephone interview. The following remarks constitute Applicants' separate record of the Substance of Interview.


Claims 29-32 have been rejected under 35 U.S.C. §103(a) as being unpatentable over U.S. Patent No. 3,042,725 to Carter et al. in view of U.S. Patent No. 3,714,265 to Bader et al.

Claims 29-33 have been canceled. Accordingly, this rejection is moot.

Claims 29-35, 37-44, 46, and 49-56 have been rejected under 35 U.S.C. §103(a) as being unpatentable over Carter in view of Bader and further in view of Kim et al. (WO 99/58100, as evidenced by US 6,579,517).

Independent claims 34 and 37 recite, among other features, a polyalkylene glycol monoallyl ether. At least this feature cannot reasonably be considered to be suggested by the applied citations.

The Advisory Action asserts, at page 2, that a polyalkylene glycol monoallyl ether does not correspond to a compound having the following structure:



However, Applicants respectfully submit that a monoallyl ether is an ether having one allyl-group. An allyl group, as set forth at page 3, lines 28-29, of Applicants' disclosure has the structure $\text{H}_2\text{C}=\text{CH}-\text{CH}_2-$. Further, as set forth at page 4, line 20, a monoallyl ether is an ether of an allyl alcohol with a polyetherdiol. In this case, R is a polyalkylene glycol.

During the July 7, 2009 telephone interview, Examiner Gillespie agreed that a monoallyl ether is a compound having the above structure. Accordingly, independent claims 34 and 37 clearly and unambiguously recite the claim feature monoallyl ether. Applicants respectfully submit that no further amendments or other submissions are necessary. Moreover, Examiner Gillespie agreed during the interview that Carter and Bader fail to suggest monoallyl ethers.

The Office Action relies on Kim for suggesting polysiloxane. Kim is not applied in a manner to cure the deficiencies of Carter and Bader discussed above.

Claims 45, 47, and 48 have been rejected under 35 U.S.C. §103(a) as being unpatentable over Carter et al. in view of Bader et al. and further in view of Kim and Dieing et al. (WO 00/49998, as evidenced by US 6,964,774).

The Office Action relies on Diening for suggesting a cross-linked polyurethane and relies on Kim for suggesting polysiloxane. However, Diening and Kim are not applied in a manner to cure the deficiencies of Carter and Bader with respect to independent claims 34 and 37, as discussed above.

In view of the above amendment, Applicants believe the pending application is in condition for allowance.

Applicants concurrently herewith submit the requisite fee for a Petition for a one-month Extension of Time. Applicants believe no additional fee is due with this response. However, if any such additional fee is due, please charge our Deposit Account No. 22-0185, under Order No. 13111-00022-US from which the undersigned is authorized to draw.

Dated: July 9, 2009

Respectfully submitted,

Electronic signature: /Georg M. Hasselmann/
Georg M. Hasselmann
Registration No.: 62,324
CONNOLLY BOVE LODGE & HUTZ LLP
1875 Eye Street, NW
Suite 1100
Washington, DC 20006
(202) 331-7111
(202) 293-6229 (Fax)
Attorney for Applicant